Safety of reduced infusion times for nivolumab plus ipilimumab (N+I) and nivolumab alone (N) in advanced melanoma

Category Primary study
JournalAnnals of Oncology
Year 2016
This article has no abstract
Epistemonikos ID: 049b7c1f4f7235310dcac952ce6a09a17e9635ea
First added on: Feb 08, 2025